|Bid||2.15 x 800|
|Ask||2.23 x 1300|
|Day's Range||2.1800 - 2.2400|
|52 Week Range||1.2300 - 3.3000|
|Beta (3Y Monthly)||1.94|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2018 - May 11, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
If you want to know who really controls Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), then you'll have to look at the makeup of its share registry. Insiders often own a large Read More...
Premier Health Group (PHGRF) (PHGI), China SXT Pharmaceuticals Inc (SXTC), eHealth Inc (EHTH), and Ekso Bionics Holdings Inc (EKSO) represent four healthcare companies determined to provide the best quality of care for consumers in need. The Company has seen impressive gains over the last few months as a result of momentum gained from several key strategic investments meant to demonstrate to both investors and consumers that the Company is determined to invest in the future of its customers. Premier Health Group (PHGRF) (PHGI) announced earlier this week that, further to its new release dated January 10, 2019, the Company has acquired all outstanding securities of Cloud Practice Inc. As a result of the acquisition, Cloud Practice's Founders, including CEO Jordan Visco, and entire support team, consisting of several software developers and sales staff, will join and work alongside the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers.
Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that its wholly-owned subsidiary, Ekso Bionics, Inc., has entered into an agreement with Zhejiang Youchuang Venture Capital Investment Co., Ltd (ZYVC) and another partner to establish a joint venture designed to develop and serve the exoskeleton market in China and other Asian markets and to create a global exoskeleton manufacturing center. Stroke is the leading cause of death in China, and about 2 million Chinese die of stroke-related illnesses every year. There are currently 12 million stroke patients in the country and the number is expected to more than double to 30 million by 2030.
Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced preliminary top line financial results for the fourth quarter and fiscal year ended December 31, 2018. Total revenue for the fourth quarter of 2018 is an estimated $3.3 million reflecting year-over-year growth of 32% compared to total revenue of $2.5 million in the fourth quarter of 2017. Total revenue for the fourth quarter of 2018 includes approximately $2.4 million in medical revenue.
While small-cap stocks, such as Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) with its market cap of US$103m, are popular for their explosive growth, investors should also be aware of their balance Read More...
Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industry use, today announced that the worldwide adoption of the EksoGT™ exoskeleton has allowed stroke and spinal cord injury patients to take 100 million steps to date (click to tweet). More than 240 leading rehabilitation centers in over 30 countries helped their patients walk 50,000 miles in the EksoGT exoskeleton— the distance of walking around the world twice. Centers utilizing the EksoGT are advancing both in-patient and outpatient rehabilitation, and collectively changing the standard of care to promote better patient outcomes.
Ekso Bionics (EKSO) delivered earnings and revenue surprises of -22.22% and -10.87%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Richmond, California-based company said it had a loss of 11 cents per share. The robotic exoskeleton company posted revenue of $2.6 million in the period. In the final minutes of trading on Wednesday, ...
If you own shares in Ekso Bionics Holdings Inc (NASDAQ:EKSO) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a Read More...
German artificial limb manufacturer Ottobock (IPO-OBH.F) plans to start selling a mechanical exoskeleton that makes manual labor for factory workers easier this week, joining a field already crowded with major industrial players and start-ups. The family-owned company has tested the 'Paexo', a wearable upper-body exoskeleton designed to ease the physical strain of repetitive overhead assembly work, on 30 workers at a Volkswagen (VOWG_p.DE) plant in Bratislava. After 80 percent of workers said they would recommend it to colleagues, Ottobock is talking to Volkswagen about using the Paexo in series production, said Soenke Roessing, head of Ottobock's Industrials unit.
Junior miners turned lower in sympathy with declining gold and silver contracts, while small biotech and medical diagnostic stocks picked up the slack, underpinned by sector funds probing new highs. September has a mixed reputation when it comes to small speculative plays, suggesting that traders focus their attention on penny stocks exhibiting the highest relative strength while avoiding falling knives that may face tax selling pressure in the fourth quarter. Low-priced energy stocks look like wild cards in this equation, with crude oil coming off lows while rising Middle East tensions add to sector buying power.
Investors recently long EKSO have made 65% with more potential upside to come. Tandem Diabetes Care, Inc. (TNDM) has traded from $2 to $34/share this year, a gain of over 1700%. This is based on improving commercial success with their diabetes business and another FDA approval in the summer.
Shares of Ekso Bionics saw big gains during the trading day but lost almost 11% in after-hours trading. The company reported second quarter results that didn’t hit estimates. Spark Therapeutics, Inc. shares closed down 27.83% on Tuesday, on significant trading volume compared to usual.
Ekso Bionics (EKSO) delivered earnings and revenue surprises of -18.18% and -2.08%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Richmond, California-based company said it had a loss of 13 cents. The robotic exoskeleton company posted revenue of $3 million in the period. In the final minutes of trading ...